Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease

被引：0
|
作者：
Yarur, A. [1 ]
Bruss, A. [1 ]
Fox, C. [1 ]
Beniwal-Patel, P. [1 ]
Patel, A. [1 ]
Berens, B. [1 ]
Naik, S. [2 ]
Stein, D. [1 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol & Hepatol, Milwaukee, WI 53226 USA
[2] Prometheus Labs, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP048
引用
下载
收藏
页码：S64 / S65
页数：2
相关论文
共 50 条
  • [31] Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
    Bodini, Giorgia
    Giannini, Edoardo G.
    Savarino, Vincenzo
    Del Nero, Lorenzo
    Lo Pumo, Sara
    Brunacci, Matteo
    De Bortoli, Nicola
    Jain, Anjali
    Tolone, Salvatore
    Savarino, Edoardo
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (05) : 452 - 456
  • [32] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [33] Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
    Liefferinckx, Claire
    Minsart, Charlotte
    Cremer, Anneline
    Amininejad, Leila
    Tafciu, Vjola
    Quertinmont, Eric
    Tops, Sophie
    Deviere, Jacques
    Gils, Ann
    van Gossum, Andre
    Franchimont, Denis
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (04) : 478 - 485
  • [34] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [35] Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
    Pudilova, K.
    Kolar, M.
    Duricova, D.
    Malickova, K.
    Hruba, V.
    Machkova, N.
    Vanickova, R.
    Mitrova, K.
    Lukas, M.
    Vasatko, M.
    Lukas, M.
    Bortlik, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S356 - S356
  • [36] EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH A SHORT-TERM RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Pudilova, Karolina
    Duricova, Dana
    Kolar, Martin
    Malickova, Karin
    Hruba, Veronika
    Machkova, Nadezda
    Vanickova, Radka
    Mitrova, Katarina
    Lukas, Martin
    Vasatko, Martin
    Lukas, Milan
    Bortlik, Martin
    GASTROENTEROLOGY, 2019, 156 (06) : S877 - S877
  • [37] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
  • [38] Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases
    Coletta, Marina
    Paroni, Moira
    Alvisi, Maria Francesca
    De Luca, Matilde
    Rulli, Eliana
    Mazza, Stefano
    Facciotti, Federica
    Lattanzi, Georgia
    Strati, Francesco
    Abrignani, Sergio
    Fantini, Massimo Claudio
    Vecchi, Maurizio
    Geginat, Jens
    Caprioli, Flavio
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (09): : 1190 - 1201
  • [39] Vedolizumab Drug Levels During Maintenance Therapy in Inflammatory Bowel Disease Patients
    Koduru, Pramoda
    Morrill, Amanda
    Abraham, Bincy
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S63 - S64
  • [40] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
12345